Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 35 of 58, showing 10 Applications out of 576 total, starting on record 341, ending on 350

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

341.

ECCT/15/06/03   DolutegrAvir With NRTIs as second-line treatment (DAWNING)
    A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy   
Principal Investigator(s)
1. Dr. Evans Inyangala Amukoye
2. Dr. Maricianah Atieno Onono
Site(s) in Kenya
1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county)
2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county)
 
29-07-2015 View

342.

ECCT/21/07/05   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa       
Principal Investigator(s)
1. Dr Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. KEMRI Walter Reed Project (Kericho county)
3. Moi University Clinical Research Centre (Uasin Gishu county)
 
09-11-2021 View

343.

ECCT/24/01/03   Doxy Short Course
    A Phase 4 Study of a 3-Day Vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection.   
Principal Investigator(s)
1. Jackson Nyangaresi Nyandoro
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
2. KEMRI CCR-PHRD (Nairobi City county)
 
18-06-2024 View

344.

ECCT/21/11/06   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease    
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI/CRDR Siaya Clinical Research Annex (Siaya county)
2. KEMRI CRDR Clinical Research Clinic Nairobi (Nairobi City county)
 
20-05-2022 View

345.

ECCT/21/10/02   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Janet Oyieko
Site(s) in Kenya
1. KEMRI CCR- Butere County Hospital (Kisumu county)
2. Strathmore University (Nairobi City county)
3. KEMRI Kondele Children’s Hospital (Kisumu county)
4. KEMRI/CRDR Siaya Clinical Research Annex (Siaya county)
5. KEMRI CRDR Clinical Research Clinic Nairobi (Nairobi City county)
6. Gertrude’s Children’s Hospital (Nairobi City county)
 
14-07-2022 View

346.

ECCT/21/07/01   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell DiseaseA Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Jessie Nyokabi Githanga
Site(s) in Kenya
1. Strathmore University Medical Center (Nairobi City county)
2. KEMRI Kondele children\'S Hospital (Kisumu county)
3. Gertrude\'s Children\'s Hospital (Nairobi City county)
 
10-11-2021 View

347.

ECCT/24/10/05   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
29-04-2025 View

348.

ECCT/24/10/04   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Aga Khan University Hospital Nairobi (Nairobi City county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
30-04-2025 View

349.

ECCT/25/07/05   Cabotegravir + Rilpivirine Lon
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studie   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Aga Khan University Hospital (Nairobi City county)
2. Moi University Clinical Research Centre (Elgeyo/Marakwet county)
3. KEMRI-WRP (Kericho county)
4. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
31-10-2025 View

350.

ECCT/24/07/02   TMC278LAHTX4002
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county)
 
16-04-2025 View